Equecabtagene Autoleucel Injection (Eque-cel) for Relapsed/Refractory Systemic Lupus Erythematosus (SLE)

A Study of Equecabtagene Autoleucel Injection (Eque-cel) in the Treatment of Relapsed/Refractory Systemic Lupus Erythematosus (SLE)

This is a single-center, open-label, exploratory clinical study to evaluate the efficacy and safety of Equecabtagene Autoleucel Injection (Eque-cel) in patients with Relapsed /refractory systemic lupus erythematosus (SLE).

Study Overview

• Status: Recruiting
• Conditions: Systemic Lupus Erythematosus (SLE); Lupus Nephritis (LN)
• Intervention / Treatment: Drug: Equecabtagene Autoleucel Injection

Detailed Description

SLE is a chronic diffuse connective tissue disease with unexplained etiology that can involve multiple systems. SLE is considered as an incurable disease and traditional SLE treatment aims at long-term remission. Eque-cel is an autologous chimeric antigen receptor T-cell (CAR-T) therapy that targets B-cell maturation antigen (BCMA), which expressed on both mature B lymphocytes and malignant plasma cells. BCMA CAR-T cells offer another potential therapeutic option to eliminate plasma cells in patients with SLE driven by abnormal antibody who still suffer recurrent attacks from conventional treatments. In this study subjects will receive a three-day consecutive lymphodepletion therapy, and 1.0×10^6 total CAR T cells/kg after enrollment. A follow-up phase will include assessments for safety, efficacy evaluation and pharmacokinetics monitoring. The duration of this trial is about 2-3 years.

• Study Type: Interventional
• Enrollment (Estimated): 6
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Lingli Dong, MD; Phone Number: +862783665519; Email: tjhdongll@163.com
• Study Contact Backup: Name: Ziwei Hu, MD; Phone Number: 13237100403; Email: 836048369@qq.com

Study Locations

• China
  • Hubei
    • Wuhan, Hubei, China, 430030
      • Recruiting
      • Tongji Hospital
      • Contact: Lingli Dong, MD; Phone Number: 02783665519; Email: tjhdongll@163.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Age≥18 years old, male or female;

2. Subjects with relapsed/refractory SLE:

   1. Subjects must be diagnosed with SLE according to the 2019 European League Against Rheumatism (EULAR) / American College of Rheumatology (ACR) classification criteria, or the 2012 Systemic Lupus International Collaborating Clinics (SLICC) criteria; the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score ≥8, with a British Isles Lupus Assessment Group 2004 (BILAG-2004) activity score of A in ≥1 organ at screening, or a BILAG-2004 activity score of B in ≥2 organs.
   2. Subjects with lupus nephritis (LN) must be diagnosed with active, biopsy-confirmed lupus nephritis of type III, IV, or V, or type III/IV combined with type V according to the 2018 International Society of Nephrology/Renal Pathology Society (ISN/RPS) criteria; the SLEDAI-2000(SLEDAI-2K) score ≥8;
   3. Regular treatment with glucocorticoids and at least two immunosuppressants，immunomodulators, antimalarials, or biologics for at least 3 months, but withpoorly-controlled symptoms or intolerance to treatment.
3. Disease-related pathogenic antibody positive: anti-nuclear antibody (ANA) positive and/or anti-dsDNA positive and/or anti-Smith positive.
4. After signing the informed consent form, subjects and their partners must be willing to use effective and reliable method of contraception, devices or medicines, within one year post Eque-cel infusion (excluding contraception safety periods).
5. Subjects must provide written informed consent before the study begin.

Exclusion Criteria:

1. Disease involved the nervous system with a BILAG-2004 activity score of Class A.
2. History of solid organ transplantation.
3. History of autologous or allogeneic stem cell transplantation.
4. History of prior cell therapy or treatment of BCMA-targeted drug.
5. Known history of primary immunodeficiency (innate or acquired). 6）Concomitant other autoimmune diseases that may interfere with the study evaluation.

7) Subjects who have received the following drugs/non-drug treatment:

1. Subjects who have used therapeutic doses of corticosteroids (defined as >20 mg/day of prednisone or equivalent) within 1 week prior to enrollment. Corticosteroids must be tapered gradually according to clinical circumstances (e.g., duration and dose of treatment, severity of disease progression, and patient condition) before discontinuation，until reaching the allowable dose range specified in the protocol. Physiological replacement therapy, topical use, and inhaled corticosteroids are permitted.
2. Subjects who have used immunosuppressants other than corticosteroids within 1 week prior to enrollment.
3. Subjects who received biologic therapies or JAK/BTK/TYK inhibitors within 2 months prior to cell infusion, including but not limited to rituximab, belimumab, or baricitinib.
4. Subjects who underwent plasmapheresis or double filtration within 1 week prior to enrollment.
5. Subjects who received investigational drugs from another interventional clinical trial within 1 month before signing the informed consent form (ICF).

6. Subjects who received treatment of the study disease with any unlisted drugs within at least 5 half-lives prior to cell infusion.

   8)Major operation or surgical treatment caused by any reason that occurred or was planned within 4 weeks before enrollment or within 12 weeks after cell infusion.

   9)History of psychoactive drug abuse and failed to withdraw, or have a history of psychiatric disorders.

   10)Subjects have uncontrolled active fungal, viral, bacterial, or other infections (with persistent infection-related signs/symptoms that have not improvedafter appropriate anti-infective therapy) or infections requiring intravenous anti-infective therapy.

   11)Positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) with abnormal peripheral blood hepatitis B virus (HBV) DNA (defined as HBV DNA ≥100 IU/mL or ≥1000 copies/mL or above the normal reference range of the testing center, or positive qualitative HBV DNA); positive for hepatitis C virus (HCV) antibody with detectable peripheral blood HCV RNA (defined as ≥1000 IU/mL); positive for human immunodeficiency virus (HIV) antibody; positive for cytomegalovirus (CMV) DNA (defined as ≥1000 IU/mL); or positive for Treponema pallidum-specific antibody with positive rapid plasma reagin (RPR) test.

   12)Blood tests: Absolute neutrophil count < 1×10^9 /L, or Absolute lymphocyte count < 0.3×10 ^ 9 /L, or hemoglobin <60 g/L。 13)Subjects with serious cardiac disease: including but not limited to unstable angina and/or myocardial infarction within 12 months before screening, any congestive heart failure (New York Heart Association[NYHA] classification ≥Grade III), and a history of severe arrhythmias; or left ventricular ejection fraction (LVEF) <45%.

   14)Subjects with severe asthma or chronic obstructive pulmonary disease (COPD). Mild or moderate asthma or COPD under stable treatment may be considered with approval from the investigator and sponsor; orarterial oxygen saturation <91% at rest.

   15）Subjects have a significant risk of severe bleeding assessed by investigator.

   16) Subjects have a severe hepatic insufficiency assessed by investigator. 17) History of severe renal disease; or an estimated glomerular filtration rate (eGFR) <30 mL/min/1.73m² calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula.

   18) History of acute cerebrovascular events, including transient ischemic attack or stroke, within 6 months prior to enrollment.

   19) Any severe and/or uncontrolled comorbid conditions that, in the investigator's opinion, may interfere with the study evaluation.

   20) Diagnosis of malignancy within 5 years prior to screening, except for cured cervical carcinoma in situ, basal cell or squamous cell skin cancer, localized prostate cancer after radical surgery, ductal carcinoma in situ of the breast after radical surgery, or papillary thyroid carcinoma.

   21) Known history of severe allergy to any component of the eque-cel injection. 22）Pregnant or lactating women. 23) Subjects with other conditions adjudicated by the investigator as unsuitable for enrollment.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: 1.0 x 10^6 CAR+ T cells; Experimental: Equecabtagene Autoleucel Injection （Eque-cel ） Drug:Equecabtagene Autoleucel Injection	Drug: Equecabtagene Autoleucel Injection; dosage form: injection, dosage: 1.0×10^6 CAR-T/kg, frequency: single dose.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Response rate of SRI-4 at 6 months after Eque-cel infusion	SLE Responder Index (SRI)-4 is defined as follows with all criteria compared to Baseline: ≥ 4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score.; No worsening of the overall condition (< 0.3 point increase in Physician's Global Assessment [PhGA]) .; No new British Isles Lupus Assessment Group (BILAG) A or more than 1 new BILAG B disease activity scores.	6 months post Eque-cel infusion.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
lupus low disease activity state (LLDAS) rate through 2 years after Eque-cel infusion	Proportions of subjects achieving LLDAS by timepoint;	up to 2 years from Eque-cel infusion
Definitions of Remission in SLE (DORIS) rate through 2 years after Eque-cel infusion	Proportions of subjects achieving remission according to the DORIS as assessed by SLEDAI-2K Scale，PhGA Scale and concomitant medication usage.	up to 2 years from Eque-cel infusion
Complete and Partial Renal Response（Lupus Nephritis Patients）through 2 years after Eque-cel infusion	Proportion of Participants Who Achieve Overall Complete and Partial Renal Response (CRR+PRR).	up to 2 years from Eque-cel infusion
Safety Endpoint -Adverse Events（AEs）	Type and incidence of AEs as Assessed by CTCAE 5.0 (except CRS and ICANS assessed according to the criteria of NCI-CTCAE v5.0).	up to 2 years from Eque-cel infusion
Pharmacokinetic Endpoint-Cmax	The maximum concentration (Cmax) of CAR VCN in peripheral blood after CAR-T infusion.	up to 2 years from Eque-cel infusion
Pharmacokinetic Endpoint-Tmax	the time for CAR VCN to reach the maximum concentration (Tmax) after CAR-T infusion.	up to 2 years from Eque-cel infusion
Pharmacokinetic Endpoint-AUC	Area under the curve of 28, 90 days and the last time point of PK detection (AUC0-28d, AUC0-90d, AUC0-last) for CAR VCN.	up to 2 years from Eque-cel infusion
Pharmacokinetic Endpoint-Cmax	The maximum concentration (Cmax) of BCMA CAR-T in peripheral blood after CAR-T infusion.	up to 90 days from Eque-cel infusion
Pharmacokinetic Endpoint-Tmax	the time for BCMA CAR-T to reach the maximum concentration (Tmax) after CAR-T infusion.	up to 90 days from Eque-cel infusion
Pharmacokinetic Endpoint-AUC	Area under the curve of 28 days, 90 days (AUC0-28d, AUC0-90) for BCMA CAR-T.	up to 90 days from Eque-cel infusion
Pharmacodynamic Endpoint- pathogenic antibodies	Changes in serum levels of pathogenic antibodies such as ANA, anti-dsDNA, and anti-Smith.	up to 2 years from Eque-cel infusion
Pharmacodynamic Endpoint- Complement levels	Changes in measures of C3, C4.	up to 2 years from Eque-cel infusion
Pharmacodynamic Endpoint-sBCMA	The concentration of soluble BCMA in peripheral blood of experimental group at each time point.	up to 2 years from Eque-cel infusion

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Immunogenicity	Presence of human anti-CAR antibodies, and titer of confirmed positive antibody in peripheral blood.	up to 2 years from Eque-cel infusion
C-reactive protein (CRP)	Changes in the levels of CRP.	up to 2 years from Eque-cel infusion
Ferritin	Changes in the levels of Ferritin.	up to 2 years from Eque-cel infusion
Interleukin-6 (IL-6)	Changes in the levels of IL-6.	up to 2 years from Eque-cel infusion
replication competent lentivirus (RCL)	The incidence of replication competent lentivirus.	up to 2 years from Eque-cel infusion
Immune cell subsets	Changes in the levels of Immune cell subsets.	up to 2 years from Eque-cel infusion
Exploratory Endpoint：TCR repertoire and Gene Expression Profile	Changes in clonal expansion and diversity of TCR repertoire assessed by single cell sequencing.	up to 2 years from Eque-cel infusion
Exploratory Endpoint： BCR repertoire and Gene Expression Profile	Changes in clonal expansion and diversity of BCR repertoire assessed by single cell sequencing.	up to 2 years from Eque-cel infusion

Collaborators and Investigators

• Sponsor: Tongji Hospital
• Collaborators: Nanjing IASO Biotechnology Co., Ltd.

Study record dates

Study Major Dates

• Study Start (Estimated): April 5, 2025
• Primary Completion (Estimated): October 31, 2027
• Study Completion (Estimated): January 10, 2028

Study Registration Dates

• First Submitted: March 5, 2025
• First Submitted That Met QC Criteria: March 24, 2025
• First Posted (Actual): March 30, 2025

Study Record Updates

• Last Update Posted (Actual): March 30, 2025
• Last Update Submitted That Met QC Criteria: March 24, 2025
• Last Verified: March 1, 2025

More Information

Terms related to this study

• Keywords: SLE; CAR T; LN
• Additional Relevant MeSH Terms: Urogenital Diseases; Male Urogenital Diseases; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Connective Tissue Diseases; Autoimmune Diseases; Immune System Diseases; Glomerulonephritis; Lupus Erythematosus, Systemic; Nephritis; Lupus Nephritis
• Other Study ID Numbers: CT103ACI002

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: upon reasonable request
• IPD Sharing Access Criteria: upon reasonable request
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No